Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

EWBullishEdwards Lifesciences Q3 results and guidance raise; CMS updated TAVR NCDnews

Medium materiality6/10

Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment

Nov 9, 2026, 11:40 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The guidance raise and stronger-than-expected TAVR sales suggest near-term revenue upside; the CMS NCD update may expand access and support procedure volume over time, though the magnitude and timing of any volume change are uncertain.

AI summary

What happened, with direct paths to the underlying reporting

Edwards Lifesciences reported Q3 sales of $1.72B (10.5% growth), raised its constant-currency full-year sales growth guidance to ~11.5% (from 10–11%), and noted CMS released a final updated national coverage determination for TAVR.

Edwards Lifesciences increased its total company sales growth guidance (constant currency) to approximately 11.5% from 10% to 11%.
Edwards reported third-quarter sales of $1.72 billion, up 10.5%, with TAVR sales of $1.24 billion (up 8.0%) and TMTT adjusted sales of $207 million (up 44.0%).
Edwards said CMS released the final, updated national coverage determination (NCD) for TAVR during the quarter.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.